See more : PCCW Limited (PCCWY) Income Statement Analysis – Financial Results
Complete financial analysis of Annovis Bio, Inc. (ANVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Annovis Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Enseval Putera Megatrading Tbk. (EPMT.JK) Income Statement Analysis – Financial Results
- Boussard & Gavaudan Holding Limited (BGHL.L) Income Statement Analysis – Financial Results
- Value8 N.V. (PREVA.AS) Income Statement Analysis – Financial Results
- YASH TRADING & FINANCE LTD. (YASTF.BO) Income Statement Analysis – Financial Results
- PT Era Mandiri Cemerlang Tbk (IKAN.JK) Income Statement Analysis – Financial Results
Annovis Bio, Inc. (ANVS)
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.79M | 16.52M | 8.48M | 3.05M | 776.26K | 111.61K | 273.37K |
| General & Administrative | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Other Expenses | 0.00 | 0.00 | -36.75K | -1.16M | -735.08K | 0.00 | 0.00 |
| Operating Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Cost & Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Interest Income | 667.90M | 182.71K | 13.34K | 47.23K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 47.23M | 0.00 | 66.00 | 84.00 |
| Depreciation & Amortization | 1.00 | 25.51M | 14.54M | 6.64M | 1.61M | 713.94K | 682.43K |
| EBITDA | -45.04M | 0.00 | 0.00 | 0.00 | 0.00 | 66.00 | 84.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.04M | -25.51M | -14.54M | -6.64M | -1.61M | -713.94K | -682.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.17M | 182.71K | 50.09K | 1.18M | 614.64K | 66.00 | 84.00 |
| Income Before Tax | -56.20M | -25.33M | -14.49M | -5.46M | -990.98K | -713.87K | -682.35K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -182.71K | -50.09K | -1.20M | -694.14K | -132.00 | -682.43K |
| Net Income | -56.20M | -25.15M | -14.44M | -4.26M | -296.84K | -713.87K | -682.35K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| EPS Diluted | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
| Weighted Avg Shares Out (Dil) | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
Annovis Bio to Participate in the 139th Yale CEO Summit
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced its Founder, President and CEO was...
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap...
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo...
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Annovis Bio Appoints Andrew Walsh as Vice President Finance
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as...
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections
BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) and developing novel and transformative therapies, announced that AD phase II/III...
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease (AD) and Parkinson's Disease (PD) announced third quarter financial results...
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson's Patients
BERWYN, Pa.--(BUSINESS WIRE)--Recent developments in biomarker research have enabled the performance of measurements of important biomarkers in plasma rather than in CSF (cerebrospinal fluid), making it possible to follow the changes in biomarkers during the course of a neurodegenerative disease...
Annovis Bio Announces Pricing of $7.5 Million Public Offering
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease, today announced the pricing of an underwritten public offering of 1,250,000 units consisting...
Annovis Bio Announces Launch of Proposed Public Offering
BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease, today announced a proposed underwritten public offering in which it intends to offer...
Source: https://incomestatements.info
Category: Stock Reports